» Articles » PMID: 17087728

Effect of Von Willebrand Disease Type 2B and Type 2M Mutations on the Susceptibility of Von Willebrand Factor to ADAMTS-13

Overview
Publisher Elsevier
Specialty Hematology
Date 2006 Nov 8
PMID 17087728
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Background: von Willebrand disease (VWD) type 2 is associated with mutations in von Willebrand factor (VWF) that affect its secretion, multimeric pattern, affinity for platelet receptors and clearance of the protein. While increased proteolysis by a disintegrin-like and metalloprotease with thrombospondin type 1 motifs-13 (ADAMTS-13) has been clearly established for VWF type 2A, only little is known about VWF types 2B and 2M in this regard.

Objectives: Sensitivity of wild-type (WT) and mutated recombinant (r) VWF to proteolysis by ADAMTS-13 was investigated to better understand the role of this process in the pathophysiology of VWD.

Methods: We used human rADAMTS-13-WT to digest 11 full-length recombinant forms of VWF carrying molecular abnormalities identified in patients with VWD type 2A (E1638K and P1648S), type 2B (InsM1303, R1306W, R1308P and V1314F) and type 2M (G1324A, E1359K, K1362T, R1374H and I1425F).

Results: Using low ionic strength conditions, all mutations induced increased proteolysis of rVWF by rADAMTS-13 as compared with rVWF-WT. The susceptibility of mutants decreased in the following order: type 2A > type 2B > type 2M > rVWF-WT. At physiological salt concentration (150 mm NaCl) the sensitivity of all rVWF to rADAMTS-13 was significantly decreased. However, type 2A and type 2B mutants still exhibited a significantly higher susceptibility to rADAMTS-13 than rVWF-WT, whereas type 2M mutants normalized.

Conclusions: Type 2M mutants and rVWF-WT exhibit a similar sensitivity to rADAMTS-13-mediated proteolysis, in agreement with the normal multimeric pattern in vivo. In VWD type 2B, the spontaneous binding to platelets and excessive degradation by ADAMTS-13 of VWF high-molecular-weight multimers may account for their clearance from plasma.

Citing Articles

The impact of aberrant von Willebrand factor-GPIbα interaction on megakaryopoiesis and platelets in humanized type 2B von Willebrand disease model mouse.

Kanaji S, Morodomi Y, Weiler H, Zarpellon A, Montgomery R, Ruggeri Z Haematologica. 2022; 107(9):2133-2143.

PMID: 35142156 PMC: 9425322. DOI: 10.3324/haematol.2021.280561.


2B von Willebrand disease diagnosis: Considerations reflecting on 2021 multisociety guidelines.

Othman M, Favaloro E Res Pract Thromb Haemost. 2022; 5(8):e12635.

PMID: 34977447 PMC: 8689114. DOI: 10.1002/rth2.12635.


Type 2B von Willebrand disease with or without large multimers: A distinction of the two sides of the disorder is long overdue.

Casonato A, Daidone V, Galletta E, Bertomoro A PLoS One. 2017; 12(6):e0179566.

PMID: 28640903 PMC: 5480883. DOI: 10.1371/journal.pone.0179566.


A genetically-engineered von Willebrand disease type 2B mouse model displays defects in hemostasis and inflammation.

Adam F, Casari C, Prevost N, Kauskot A, Loubiere C, Legendre P Sci Rep. 2016; 6:26306.

PMID: 27212476 PMC: 4876317. DOI: 10.1038/srep26306.


Misfolding of vWF to pathologically disordered conformations impacts the severity of von Willebrand disease.

Tischer A, Madde P, Moon-Tasson L, Auton M Biophys J. 2014; 107(5):1185-1195.

PMID: 25185554 PMC: 4156683. DOI: 10.1016/j.bpj.2014.07.026.